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sis uses a cohort Markov model to estimate lifetime costs and
QALYs to extrapolate observed clinical trial results (the BIG 
1-98 trial). The model was designed to describe all the relevant
states during the disease course and to capture the incidence 
and costs of all the relevant adverse events the letrozole and
tamoxifen patient groups: endometrial cancer; bone fractures;
myocardial infarction; venous thromboembolic events; and
hypercholesterolaemia. Cost items were obtained from ofﬁcial
data sources and were attached to estimate the resource use by
patients spending a year in each of the health states included in
the model, as well as to resources used to treat the mentioned
AEs. The utility parameters associated with the model’s breast
cancer states are based on a primary utility study, that used the
standard gamble approach to estimate utility values for breast-
cancer related health states. RESULTS: Letrozole treatment for
breast cancer in the early adjuvant setting resulted an additional
388 (discounted) years of disease free survival are gained, with
250 life years, and 277 quality adjusted life years (QALYs). The
incremental cost per life year was HUF 6,060,371, and the incre-
mental cost per QALY was HUF 5,462,685. The lower cost per
QALY than cost per life year gained indicates that the difference
in the utility gained as result of fewer patients experiencing a
distant recurrence outweighs the gain in life years due to the sur-
vival impact of distant recurrence. CONCLUSION: Our cost
utility analyses showed that letrozole was cost-effective as a
treatment for postmenopausal oestrogen receptor positive
women following diagnosis with early breast cancer in Hungary.
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RETROSPECTIVE COMPARATIVE PHARMACOECONOMIC
ANALYSIS OF VARIOUS TREATMENT SCHEMES IN PATIENTS
WITH ADVANCED HODGKIN’S DISEASE
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Center of the Russian Academy of Medical Sciences, Moscow, Russia
OBJECTIVE: To compare cost and effectiveness of various
schemes of treatment patients with advanced Hodgkin’s disease
and to determine more cost-effective schemes in Russia.
METHODS: In order to determine quantity of drugs and cost of
different treatment schemes we used data from individual
medical documentation (history of disease) in Hematological
Scientiﬁc Center and data from price-lists of pharmaceutical dis-
tributors in Moscow. In order to determine effectiveness we ana-
lyzed data from clinical trials. We chose data from clinical trials,
which is possible to compare. It was data from clinical trial,
which guided German Hodgkin Study Group (GHSG). In this
trial scientists estimated 3 years Freedom from Treatment Failure
(FFTF) of 4 schemes: COPP/ABVD, BEACOPP-baseline,
BEACOPP-escalated and BEACOPP-14. In the end, we calcu-
lated and analyzed cost-effectiveness rates (CER) of different
schemes. RESULTS: Effectiveness of investigating schemes (3
year FFTF) was 70% for COPP/ABVD, 79% for BEACOPP-
baseline, 89% for BEACOPP-escalated and 90% for BEACOPP-
14. Cost of treatment by these schemes was 138,600 rubles
(€3960), 125,500 rubles (€3586), 537,900 rubles (€15,370), and
503,900 rubles (€14,400) (35 rubles = 1 Euro) for COPP/ABVD,
BEACOPP-baseline, BEACOPP-escalated and BEACOPP-14,
respectively. CER for these schemes was 1979, 1588, 6043, and
5598 rubles per percent or 57, 45, 173, and 160 euros per
percent, for COPP/ABVD, BEACOPP-baseline, BEACOPP-esca-
lated and BEACOPP-14, respectively. BEACOPP-baseline had
minimal CER but BEACOPP-escalated and BEACOPP-14 were
more effective and more expensive. BEACOPP-14 was less
expensive and more effective than BEACOPP-escalated. Thus,
BEACOPP-baseline and BEACOPP-14 are more cost-effective
than COPP/ABVD and BEACOPP-escalated, respectively. CON-
CLUSIONS: We compared cost and effectiveness of 4 therapy
schemes of advanced Hodgkin’s disease and determined more
cost-effective schemes (BEACOPP-baseline and BEACOPP-14).
In order to choose between BEACOPP-baseline and BEACOPP-
14 we have to know budget, which payer has, or price, which
payer is able to pay for treatment.
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COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL
MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN
PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) 
IN SPAIN
Brosa M1,Arocho R2
1Oblikue Consulting, Barcelona, SC, Spain, 2Amgen SA, Barcelona,
Spain
OBJECTIVE: OM is a frequent, serious, and one of the most
debilitating side effect among patients who undergo myelosup-
pressive therapy and hematologic stem cell transplants. Palifer-
min is the ﬁrst and only mucosal growth factor indicated to
decrease the incidence, duration and severity of OM in patients
with haematological malignancies receiving myeloablative
therapy associated with a high incidence of severe mucositis and
requiring ASCT. Assess palifermin CE in the prevention of OM
in patients requiring ASCT in Spain. METHODS: CE was
assessed based on a palifermin phase 3 clinical trial (1) compar-
ing palifermin with best supportive care (BSC), local mean hos-
pital costs (1051,50€ per-diem) (2) and assuming palifermin
ex-manufacturer price of 4.700€/treatment. A sensitivity analy-
sis applying a correction factor of 15% to hospital cost since
severity of OM is associated with an increase utilization of health
care resources. (3) Effectiveness measured in terms of number
days reduction with OM and decrease of grades 3/4 OM inci-
dence. RESULTS: Compared to BSC, palifermin effectively
decreased the duration of severe (WHO grade 3 or 4) OM from
9 to 3 days (p < 0.001) (1), and was associated with a lower inci-
dence of severe OM (98% vs 63%; p < 0.001) (1), and reduced
post-transplant inpatient stay by 1.9 days (from 17,2 to 15,3; p
= 0,008) (4). The CE model shows an incremental cost-effec-
tiveness ratio (ICER) of using palifermin over BSC of 7.720,43€
per episode of grade 3/4 OM avoided and an ICER of 450,36€
per day of grade 3/4 OM avoided. Adjusting for severity of OM,
the ICER are €825,60 per episode of grade 3/4 OM avoided and
€48,16 per day of grade 3/4 OM avoided. CONCLUSIONS: Pal-
ifermin is a cost-effective therapy for ASCT patients. When
taking into account the impact of OM severity OM on health
care resources, palifermin could be a cost-neutral intervention.
[1] Spielberger R, et al. N Engll 2004 Dec 16;351:2590–8 2
Spain MOH (MSC 2002) 3 Sonis, et al. Journal Clinical Oncol-
ogy. 2001;19:2201–2205 4 Emmanouilides C, et al. Blood
2003;102(11): Abstract #883.
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STAGE NON-HODGKIN’S LYMPHOMA (NHL)
Hieke K1, Herold M2
1NEOS Health, Binningen, Switzerland, 2HELIOS Klinikum Erfurt,
Erfurt, Germany
OBJECTIVES: To identify cost and cost effectiveness of R-MCP
(rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP
in NHL-patients from the perspective of a third party payer in
Germany (statutory sickness fund). METHODS: Resource uti-
lization data on 329 patients were collected in parallel to a RCT
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and analyzed for the treatment phase. In addition, an interim
analysis of the subsequent observation period was conducted.
Patients were treated before the DRG-system was introduced in
Germany. Therefore, length of each hospitalisation was used as
proxy for case-complexity and as criterion for assignment to one
of 3 DRGxs relevant for NHL-patients. Several sensitivity analy-
ses were performed to address different DRG-grouping criteria
and discounting scenarios. RESULTS: Mean cost per treatment
cycle was €2700 for R-MCP and €1900 for MCP (p < 0.0001).
Mean observation periods after end of initial treatment were
21.2 months for R-MCP and 17.6 months for MCP (p = 0.02).
Hospitalisations for adverse events (−32%), new chemotherapies
(−33%), treatment of progressive disease (−55%) and other
reasons (−39%) were reduced in the R-MCP arm. This resulted
in mean, undiscounted cost per patient in the observation period
of €4600 for R-MCP and €7700 for MCP (p = 0.02). To adjust
for the difference in length of the observation period overall
monthly costs were calculated and amounted to €1230 for R-
MCP and €1290 for MCP (p = 0.67). Sensitivity analyses did not
result in major changes. Clinically, R-MCP resulted in an objec-
tive response rate of 85.6% vs. 65.5% with MCP. After two
years event free survival for R-MCP was 69% vs. 44% for MCP
alone (p < 0.001). CONCLUSION: Initially higher treatment
costs of R-MCP were compensated by savings due to better efﬁ-
cacy. Combined with the clinical superiority of R-MCP, this
regime is likely to prevail as the dominant treatment strategy
compared to MCP alone at the ﬁnal analysis.
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PEGFILGRASTIM PRIMARY PROPHYLAXIS IS MORE COST-
EFFECTIVE THAN FILGRASTIM IN WOMEN WITH BREAST
CANCER RECEIVING CHEMOTHERAPY IN FRANCE
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OBJECTIVES: In breast cancer, primary prophylaxis with peg-
ﬁlgrastim has been shown to improve health outcomes but its
cost-effectiveness has not been evaluated in the French setting.
Filgrastim is often used for less than the recommended 11 days
(e.g., 5–6 days), which has been associated with sub-optimal out-
comes. This study compared the cost-effectiveness of pegﬁlgras-
tim versus 11- and 6-day ﬁlgrastim primary prophylaxis in
women with stage I–III breast cancer receiving chemotherapy
with moderate to high FN risk in France. METHODS: A deci-
sion-analytic model was constructed from a health care payer’s
perspective. Costs included drugs, drug administration, FN-
related hospitalizations and subsequent costs, and were based on
ex-factory price listing and DRG Tariff. Effectiveness was mea-
sured as FN avoided and life-year-gained (LYG). FN risk (varied
by days of ﬁlgrastim), FN case-fatality, relative dose intensity
(RDI), and the impact of RDI on survival were based on a com-
prehensive literature review and expert panel validation. Breast
cancer mortality and all-cause mortality were taken from ofﬁcial
statistics. Model robustness was tested using sensitivity analyses.
RESULTS: Compared with 11 days of ﬁlgrastim, pegﬁlgrastim
saved costs and was more effective. Compared with 6-day 
ﬁlgrastim, pegﬁlgrastim avoided 10.5 absolute percentage point
of FN (17.5% vs. 7%). The incremental cost-effectiveness 
ratio (ICER) was €10,295 per FN avoided. The average life
expectancy was 16.27 years with pegﬁlgrastim and 16.16 years
with ﬁlgrastim, yielding an ICER of €9652/LYG. Age of diag-
nosis and cancer stage had minimal impact on the results. Key
inﬂuencing factors included relative costs of drugs and relative
risk of FN. CONCLUSIONS: Use of pegﬁlgrastim in France may
dominate 11-day use of ﬁlgrastim and is cost-effective compared
to 6-day use of ﬁlgrastim. The cost-effectiveness ratio is signiﬁ-
cantly below the commonly used threshold for cost-effectiveness
ratios in Europe.
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TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL
CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE
PRACTICE: A COST OF ILLNESS AND MODEL VALIDATION
STUDY
Caekelbergh K,Annemans L
IMS Health Economics and Outcomes Research (HEOR), Brussels,
Belgium
OBJECTIVES: An original decision model has shown that
methyl-aminolevulinate (MAL) is a cost-effective intervention in
AK and better value for money than excision in BCC. The objec-
tive of this observational study was to conﬁrm these results in
real life in Belgium from a health-care-payers perspective.
METHODS: The study was a prospective, multi-centre obser-
vational study in which patients meeting criteria for MAL-
treatment were followed for 6 months after ﬁrst application of
methyl-aminolevulinate. Clinical response (CR) and cosmetic
outcome (CO) were evaluated at the last available visit during
the follow-up period. Socio-demographic data, treatment related
data and safety data were collected. Inclusion period was
October 2004–October 2005. RESULTS: 247 patients were eval-
uated (mean age: 69 years; 53% males). 47% of patients had AK
with an average of 7.1 ± 0.4 lesions (32% new lesions); BCC-
patients had an average of 1.7 ± 0.2 lesions (89% new lesions).
As the majority of patients had multiple lesions, on average
0.797 tube of MAL was used per patient. AK patients had a
mean of 3.9 dermatologist visits related to diagnosis, treatment
and follow-up (BCC: 4.2 visits). In 83% of AK and in 84% of
BCC patients, all lesions showed a complete CR. Good to excel-
lent CO was found in 95% and 93% of AK and BCC patients
respectively. Total cost of care (MAL-treatment plus follow-up)
was €383 in AK and €298 in BCC-patients, with a higher effec-
tiveness compared to the model. The model showed €255 for AK
and €303 for BCC. Higher costs in AK were due to a higher
mean number of lesions per patient compared to the model pop-
ulation (4.1 lesions per patient). CONCLUSIONS: This obser-
vational study conﬁrms the cost-effectiveness shown in the
original model for methyl-aminolevulinate in AK and BCC and
shows that real-life data can be used to reﬁne original decision
models.
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OBJECTIVE: To compare the cost-effectiveness of therapy with
erlotinib (ERL), docetaxel (DOC), pemetrexed (PEM) or best
supportive care (BSC) in patients with advanced non-small cell
lung cancer (NSCLC) in Spain. METHODS: A Markov model
with 3 health states (progression free, disease progression and
dead) was developed. Time horizon: 2 years (monthly cycles).
Survival and time to progression were obtained from 3 clinical
trials. Utilities were obtained from a study performed in UK in
154 patients. National Health System (NHS) perspective (direct
health costs) was applied. Resources used were estimated from
